eli lilly glp-1 drugs Study flags need to monitor frailty risks with for older adults As GLP-1 Use Expands, Long-Term

The SURMOUNT-1 study was a placebo-controlled 72-week trial in obese subjects that randomized 2,539 participants without diabetes into four equally large study arms with placebo or one of the three tirzepatide doses (5, 10, or 15 mg once weekly)

doi:10.2165/00003088-199324050-00007 222

[DOI] [PMC free article] [PubMed] [Google Scholar] 94.Activation of spinal glucagon-like peptide-1 receptors specifically suppresses pain hypersensitivity

52,53 In a phase 2, multi-center trial conducted at 45 centers, orforglipron at doses of 12 mg or greater showed significant reductions in HbA1c and bodyweight compared with placebo or dulaglutide

289 , H2401H2408 (2005)

22 Multi-purpose retailers are likely to be less impacted due to a typically diverse offering, while those with pharmacies could see higher sales and increased foot traffic through offering GLP-1RAs